Novo Nordisk now has an Ozempic pill. Citing a Novo spokesperson, pharmaceuticals news site BioPharmaDive reported yesterday ...

Shares of Novo Nordisk, the Danish pharmaceutical company behind weight-loss drugs Ozempic and Wegovy, plummeted this week.

Even though the stock is down notably from the peak price it hit last year, it's still doing far better than in the pre-approval days. Competitors are biting at its heels in the weight loss segment, ...

BMO Capital downgraded Novo Nordisk (NVO) to Market Perform from Outperform with a price target of $64, down from $105. The company’s obesity ...

Danish drugmaker Novo Nordisk said on Monday several hundred counterfeit units of its diabetes drug Ozempic were being ...

https://www.tipranks.com/news/the-fly/novo-nordisk-warns-of-counterfeit-ozempic-injections Novo Nordisk (NVO) said it has become aware of several hundred units of ...

Investing.com -- BMO Capital Markets downgraded Novo Nordisk (NYSE:NVO) to “Market Perform” from “Outperform” and cut its price target to $64, saying the Danish drugmaker’s early lead in ...

Novo Nordisk (NVO) has become aware of several hundred units of Ozempic injection 1 mg distributed outside the Novo Nordisk authorized supply chain in the U.S., the company announced.The Food and ...

Analyst downgrades Novo Nordisk, cuts price target to $64. The analyst highlights that Lilly's drugs, Mounjaro and Zepbound, will gain U.S. market share from Novo Nordisk's Ozempic and Wegovy.

Weight loss leader Novo Nordisk has had a poor performance at the stock markets year-to-date [YTD] even as the healthcare sector is among the least impacted ones. The key reason for this is ...